LIVE
A research blend co-dosing the GLP-1 receptor agonist semaglutide with the amylin analog cagrilintide. Novo Nordisk's combination product CagriSema pairs these same two molecules at a 1:1 ratio in Phase 3 obesity and type 2 diabetes trials, targeting additive weight-loss and glycemic benefits versus either agent alone. Vendor preparations typically dose per-component in a single vial for co-administration.
For research purposes only. Not medical advice.
Glow Aminos currently lists Semaglutide + Cagrilintide Blend at $4.95/mg, the lowest indexed price across 4 tracked research peptide vendors.
Semaglutide + Cagrilintide Blend ranges from $4.95/mg to $9.90/mg across 5 listings from 4 research peptide vendors, normalized to USD per milligram and refreshed daily.
4 research peptide vendors currently list Semaglutide + Cagrilintide Blend on PeptideScouter. We track 5 active listings across size and kit variants.
